Infectious Disease Diagnostics Market Size, Share & Trends

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Infectious Disease Diagnostics Market Size Analysis

Global Infectious Disease Diagnostics Market Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Hepatitis
  1. By Value
3. Human Immunodeficiency Virus (HIV)
  1. By Value
4. Chlamydia Trachomatis Genital Infection
  1. By Value
5. Gonorrhea (CT/NG)
  1. By Value
6. Hospital-Acquired Infections
  1. By Value
7. Human Papillomavirus (HPV)
  1. By Value
8. Tuberculosis (TB)
  1. By Value
9. Influenza
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Instruments
  1. By Value
4. Services and Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
4. Immunodiagnostics
  1. By Value
5. DNA Microarray
  1. By Value
6. Clinical Microbiology
  1. By Value
7. DNA Sequencing and Next-Generation Sequencing (NGS)
  1. By Value

North America Market Analysis

Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Hepatitis
  1. By Value
3. Human Immunodeficiency Virus (HIV)
  1. By Value
4. Chlamydia Trachomatis Genital Infection
  1. By Value
5. Gonorrhea (CT/NG)
  1. By Value
6. Hospital-Acquired Infections
  1. By Value
7. Human Papillomavirus (HPV)
  1. By Value
8. Tuberculosis (TB)
  1. By Value
9. Influenza
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Instruments
  1. By Value
4. Services and Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
4. Immunodiagnostics
  1. By Value
5. DNA Microarray
  1. By Value
6. Clinical Microbiology
  1. By Value
7. DNA Sequencing and Next-Generation Sequencing (NGS)
  1. By Value
U.S.
1. By Applications
  1. Introduction
    1. Applications By Value
  2. Hepatitis
    1. By Value
  3. Human Immunodeficiency Virus (HIV)
    1. By Value
  4. Chlamydia Trachomatis Genital Infection
    1. By Value
  5. Gonorrhea (CT/NG)
    1. By Value
  6. Hospital-Acquired Infections
    1. By Value
  7. Human Papillomavirus (HPV)
    1. By Value
  8. Tuberculosis (TB)
    1. By Value
  9. Influenza
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Assays, Kits, and Reagents
    1. By Value
  3. Instruments
    1. By Value
  4. Services and Software
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Isothermal Nucleic Acid Amplification Technology (INAAT)
    1. By Value
  4. Immunodiagnostics
    1. By Value
  5. DNA Microarray
    1. By Value
  6. Clinical Microbiology
    1. By Value
  7. DNA Sequencing and Next-Generation Sequencing (NGS)
    1. By Value
Canada

Europe Market Analysis

Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Hepatitis
  1. By Value
3. Human Immunodeficiency Virus (HIV)
  1. By Value
4. Chlamydia Trachomatis Genital Infection
  1. By Value
5. Gonorrhea (CT/NG)
  1. By Value
6. Hospital-Acquired Infections
  1. By Value
7. Human Papillomavirus (HPV)
  1. By Value
8. Tuberculosis (TB)
  1. By Value
9. Influenza
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Instruments
  1. By Value
4. Services and Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
4. Immunodiagnostics
  1. By Value
5. DNA Microarray
  1. By Value
6. Clinical Microbiology
  1. By Value
7. DNA Sequencing and Next-Generation Sequencing (NGS)
  1. By Value
U.K.
1. By Applications
  1. Introduction
    1. Applications By Value
  2. Hepatitis
    1. By Value
  3. Human Immunodeficiency Virus (HIV)
    1. By Value
  4. Chlamydia Trachomatis Genital Infection
    1. By Value
  5. Gonorrhea (CT/NG)
    1. By Value
  6. Hospital-Acquired Infections
    1. By Value
  7. Human Papillomavirus (HPV)
    1. By Value
  8. Tuberculosis (TB)
    1. By Value
  9. Influenza
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Assays, Kits, and Reagents
    1. By Value
  3. Instruments
    1. By Value
  4. Services and Software
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Isothermal Nucleic Acid Amplification Technology (INAAT)
    1. By Value
  4. Immunodiagnostics
    1. By Value
  5. DNA Microarray
    1. By Value
  6. Clinical Microbiology
    1. By Value
  7. DNA Sequencing and Next-Generation Sequencing (NGS)
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Hepatitis
  1. By Value
3. Human Immunodeficiency Virus (HIV)
  1. By Value
4. Chlamydia Trachomatis Genital Infection
  1. By Value
5. Gonorrhea (CT/NG)
  1. By Value
6. Hospital-Acquired Infections
  1. By Value
7. Human Papillomavirus (HPV)
  1. By Value
8. Tuberculosis (TB)
  1. By Value
9. Influenza
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Instruments
  1. By Value
4. Services and Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
4. Immunodiagnostics
  1. By Value
5. DNA Microarray
  1. By Value
6. Clinical Microbiology
  1. By Value
7. DNA Sequencing and Next-Generation Sequencing (NGS)
  1. By Value
China
1. By Applications
  1. Introduction
    1. Applications By Value
  2. Hepatitis
    1. By Value
  3. Human Immunodeficiency Virus (HIV)
    1. By Value
  4. Chlamydia Trachomatis Genital Infection
    1. By Value
  5. Gonorrhea (CT/NG)
    1. By Value
  6. Hospital-Acquired Infections
    1. By Value
  7. Human Papillomavirus (HPV)
    1. By Value
  8. Tuberculosis (TB)
    1. By Value
  9. Influenza
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Assays, Kits, and Reagents
    1. By Value
  3. Instruments
    1. By Value
  4. Services and Software
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Isothermal Nucleic Acid Amplification Technology (INAAT)
    1. By Value
  4. Immunodiagnostics
    1. By Value
  5. DNA Microarray
    1. By Value
  6. Clinical Microbiology
    1. By Value
  7. DNA Sequencing and Next-Generation Sequencing (NGS)
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Hepatitis
  1. By Value
3. Human Immunodeficiency Virus (HIV)
  1. By Value
4. Chlamydia Trachomatis Genital Infection
  1. By Value
5. Gonorrhea (CT/NG)
  1. By Value
6. Hospital-Acquired Infections
  1. By Value
7. Human Papillomavirus (HPV)
  1. By Value
8. Tuberculosis (TB)
  1. By Value
9. Influenza
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Instruments
  1. By Value
4. Services and Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
4. Immunodiagnostics
  1. By Value
5. DNA Microarray
  1. By Value
6. Clinical Microbiology
  1. By Value
7. DNA Sequencing and Next-Generation Sequencing (NGS)
  1. By Value
UAE
1. By Applications
  1. Introduction
    1. Applications By Value
  2. Hepatitis
    1. By Value
  3. Human Immunodeficiency Virus (HIV)
    1. By Value
  4. Chlamydia Trachomatis Genital Infection
    1. By Value
  5. Gonorrhea (CT/NG)
    1. By Value
  6. Hospital-Acquired Infections
    1. By Value
  7. Human Papillomavirus (HPV)
    1. By Value
  8. Tuberculosis (TB)
    1. By Value
  9. Influenza
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Assays, Kits, and Reagents
    1. By Value
  3. Instruments
    1. By Value
  4. Services and Software
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Isothermal Nucleic Acid Amplification Technology (INAAT)
    1. By Value
  4. Immunodiagnostics
    1. By Value
  5. DNA Microarray
    1. By Value
  6. Clinical Microbiology
    1. By Value
  7. DNA Sequencing and Next-Generation Sequencing (NGS)
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Applications
1. Introduction
  1. Applications By Value
2. Hepatitis
  1. By Value
3. Human Immunodeficiency Virus (HIV)
  1. By Value
4. Chlamydia Trachomatis Genital Infection
  1. By Value
5. Gonorrhea (CT/NG)
  1. By Value
6. Hospital-Acquired Infections
  1. By Value
7. Human Papillomavirus (HPV)
  1. By Value
8. Tuberculosis (TB)
  1. By Value
9. Influenza
  1. By Value
By Product
1. Introduction
  1. Product By Value
2. Assays, Kits, and Reagents
  1. By Value
3. Instruments
  1. By Value
4. Services and Software
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase Chain Reaction (PCR)
  1. By Value
3. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
4. Immunodiagnostics
  1. By Value
5. DNA Microarray
  1. By Value
6. Clinical Microbiology
  1. By Value
7. DNA Sequencing and Next-Generation Sequencing (NGS)
  1. By Value
Brazil
1. By Applications
  1. Introduction
    1. Applications By Value
  2. Hepatitis
    1. By Value
  3. Human Immunodeficiency Virus (HIV)
    1. By Value
  4. Chlamydia Trachomatis Genital Infection
    1. By Value
  5. Gonorrhea (CT/NG)
    1. By Value
  6. Hospital-Acquired Infections
    1. By Value
  7. Human Papillomavirus (HPV)
    1. By Value
  8. Tuberculosis (TB)
    1. By Value
  9. Influenza
    1. By Value
2. By Product
  1. Introduction
    1. Product By Value
  2. Assays, Kits, and Reagents
    1. By Value
  3. Instruments
    1. By Value
  4. Services and Software
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase Chain Reaction (PCR)
    1. By Value
  3. Isothermal Nucleic Acid Amplification Technology (INAAT)
    1. By Value
  4. Immunodiagnostics
    1. By Value
  5. DNA Microarray
    1. By Value
  6. Clinical Microbiology
    1. By Value
  7. DNA Sequencing and Next-Generation Sequencing (NGS)
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Infectious Disease Diagnostics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Biomerieux Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Abbott Laboratories
Becton, Dickinson and Company
Bio-Rad Laboratories Inc.
Danaher Corporation
F. Hoffmann-La Roche Ag
Siemens Healthcare Gmbh
Thermo Fisher Scientific Inc
Quidel Corporation
Diasorin Spa (Luminex Corporation)
Trinity Biotech Plc
Quest Diagnostics
Sysmex Corporation
Ortho-Clinical Diagnostics
Seegene Inc

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment